A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
Sponsor: InventisBio Co., Ltd
This PHASE1 trial investigates Breast Cancer and is currently completed. InventisBio Co., Ltd leads this study, which shows 13 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
13 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Feb 2024 — Jul 2024 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE1
-
Jun 2022 — May 2023 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 8 earlier versions
-
Feb 2022 — Jun 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Feb 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting PHASE1
-
Jul 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Sep 2019 — Jul 2020 [monthly]
Recruiting PHASE1
-
Jul 2018 — Sep 2019 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Jun 2018 — Jul 2018 [monthly]
Not Yet Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- InventisBio Co., Ltd
For direct contact, visit the study record on ClinicalTrials.gov .